BioXcel Therapeutics Inc BTAI:NASDAQ

Last Price$17.62NASDAQ Previous Close - Last Trade as of 4:00PM ET 4/03/20

Today's Change-1.13(6.03%)
Bid (Size)$17.70 (2)
Ask (Size)$18.50 (2)
Day Low / High$16.00 - 19.42
Volume416.3 K

View Biotechnology IndustryPeer Comparison as of 04/03/2020


BioXcel Therapeutics Inc ( NASDAQ )

Price: $17.62
Change: -1.13 (6.03%)
Volume: 416.3 K
4:00PM ET 4/03/2020


Price: $9.75
Change: -0.45 (4.41%)
Volume: 444.2 K
8:00PM ET 4/03/2020

Scholar Rock Holding Corp ( NASDAQ )

Price: $14.42
Change: +1.63 (12.74%)
Volume: 95.3 K
4:00PM ET 4/03/2020

Agenus Inc ( NASDAQ )

Price: $2.37
Change: 0.00 (0.00%)
Volume: 1.2 M
4:00PM ET 4/03/2020

Verastem Inc ( NASDAQ )

Price: $2.47
Change: -0.12 (4.83%)
Volume: 872.8 K
4:00PM ET 4/03/2020

Read more news Recent News

--Analyst Actions: BofA Securities Initiates BioXcel Therapeutics Coverage at Buy, Price Target $45
11:11AM ET 4/01/2020 MT Newswires

Price: 21.63, Change: -0.72, Percent Change: -3.22 ...

BioXcel Therapeutics Doses More Than One-Third of Patients in Anti-Agitation Treatment Study
8:26AM ET 3/19/2020 MT Newswires

BioXcel Therapeutics (BTAI) said pre-market Thursday that more than one-third of the patients in the phase 3 trials of its investigative anti-agitation...

--Analyst Actions: HC Wainwright Raises Price Target for Buy-Rated BioXcel Therapeutics to $95 From $30, Shares Rally 11%
2:18PM ET 2/26/2020 MT Newswires

Price: 33.11, Change: +3.38, Percent Change: +11.37 ...

--Analyst Actions: Canaccord Genuity Lifts Price Target on BioXcel Therapeutics to $68 From $27, Reiterates Buy Rating
10:07AM ET 2/21/2020 MT Newswires

Price: 35.18, Change: +0.98, Percent Change: +2.87 ...

Company Profile

Business DescriptionBioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT. View company web site for more details
Address555 Long Wharf Drive
New Haven, Connecticut 06511
Number of Employees18
Recent SEC Filing03/09/20208-K
President, CEO, Secretary & DirectorVimal D. Mehta
Chief Financial Officer & Vice PresidentRichard I. Steinhart
Chief Scientific OfficerFrank D. Yocca
Chief Medical Officer & Senior Vice PresidentVincent J. O'Neill

Company Highlights

Price Open$18.82
Previous Close$18.75
52 Week Range$3.76 - 43.63
Market Capitalization$355.6 M
Shares Outstanding20.2 M
SectorHealth Technology
Next Earnings Announcement05/05/2020

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$2.03
Beta vs. S&P 500N/A
Net Profit MarginN/A
Return on Equity-110.97%

Analyst Ratings as of 04/01/2020

Consensus RecommendationConsensus Icon
Powered by Factset